Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.
Dabrowska, A.; Szczepanski, A.; Botwina, P.; Mazur-Panasiuk, N.; Jirincova, H.; Rabalski, L.; Zajic, T.; Popowicz, G.; Pyrc, K.
Show abstract
The Omicron variant of the SARS-CoV-2 virus was first detected in South Africa in November 2021. The analysis of the sequence data in the context of earlier variants suggested that it may show very different characteristics, including immune evasion and increased transmission. These assumptions were partially confirmed, and the reduction in protection in convalescent patients and vaccinated individuals have been confirmed. Here, we have evaluated the efficacy of antivirals against SARS-CoV-2 variants, Omicron, Delta, and the early 2020 isolate.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. 96%
- Identification of novel Ebola virus inhibitors using biologically contained virus 95%
- Assessing Human Liver Spheroids as a Model for Antiviral Drug Evaluation Against BSL-3 Haemorrhagic Fever viruses 95%
Similar papers in this journal
- Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell 95%
- Repurposing of the antibiotic nitroxoline for the treatment of mpox 95%
- In Vitro Activity of Itraconazole Against SARS-CoV-2 94%
Similar papers in this journal
- Potential antiviral options against SARS-CoV-2 infection 95%
- Targeting Host PIM Protein Kinases Reduces Mayaro Virus Replication 94%
- The combination of GS-441524 (remdesivir) and ribavirin results in a potent antiviral effect against human parainfluenza virus 3 infection in human airway epithelial cell cultures and in a mouse infection model 93%
Similar papers in this journal
- Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against Respiratory Syncytial Virus 93%
- The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines 92%
- Inactivation of SARS-CoV-2 by β-propiolactone Causes Aggregation of Viral Particles and Loss of Antigenic Potential 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.